2nd SOHO Italian Conference

http://www.sohoitaly.it/

 

2nd SOHO Italian Conference
Avatar

How I Treat Frontline CML: What Are the Differences in ELTS vs. Sokal’s Risk Score? Does Imatinib OS Differ in High/Intermediate/Low-Risk Patients? Should We Discontinue TKIs in Some Groups?

By 2nd SOHO Italian Conference FEATURING Giuseppe Saglio
By 2nd SOHO Italian Conference FEATURING Giuseppe Saglio
8 views
January 27, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
Leukemia
14:51
2nd SOHO Italian Conference

MRD & ALL Management: What Role Does It Play in AlloHSCT Setting?

Feat. A. Rambaldi
17:00
2nd SOHO Italian Conference

How I Treat AML at MD Anderson: ATRA & GO Combos, Sequential HD …

Feat. H. Kantarjian
09:43
2nd SOHO Italian Conference

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibit…

Feat. H. Kantarjian
10:02
2nd SOHO Italian Conference

How I Treat ALL at MD Anderson: What Hyper-CVAD Combinations Showed …

Feat. H. Kantarjian
13:11
2nd SOHO Italian Conference

MD Anderson Future Directions in ALL: How Effective Are New Blina/In…

Feat. H. Kantarjian
13:38
2nd SOHO Italian Conference

TFR and CML: Why Is TFR Important? What Happens After? Why Is It Dif…

Feat. E. Abruzzese
08:52
2nd SOHO Italian Conference

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR Af…

Feat. M. Malagola
14:09
2nd SOHO Italian Conference

How I Treat Frontline CML: What Are the Differences in ELTS vs. Soka…

Feat. G. Saglio
09:15
2nd SOHO Italian Conference

Post-SCT Maintenance in AML: What Is the Role of Hypomethylating Age…

Feat. A. Sperotto
15:37
2nd SOHO Italian Conference

Allogenic Transplant in AML: How Does ASCT Compare to Chemo in Older…

Feat. A. Olivieri
13:56
2nd SOHO Italian Conference

MRD Assessment in Frontline AML: What Are the Characteristics of Dif…

Feat. F. Buccisano
09:22
2nd SOHO Italian Conference

Prognostic Relevance of BPDCN-Like Phenotype in Newly Diagnosed AML:…

Feat. R. Lemoli
11:45
2nd SOHO Italian Conference

Pro-Apoptotic Pathways in AML: How Does Venetoclax Work in Combinati…

Feat. S. Galimberti
14:40
2nd SOHO Italian Conference

Genomic Sequencing in AML and MDS: How Can We Define Subtypes and Mu…

Feat. I. Iacobucci
12:17
2nd SOHO Italian Conference

Novel mAbs in ALL: Is Ino Better than SoC? What Is the MRD-Negativit…

Feat. F. Lanza
10:44
2nd SOHO Italian Conference

mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease…

Feat. C. Papayannidis
08:04
2nd SOHO Italian Conference

Cell Morphology in Acute Leukemias & Hematologic Malignancies: D…

Feat. G. Zini
11:05
2nd SOHO Italian Conference

Synthetic Lethality Against ALL: How Often Is the Expression of DDR-…

Feat. A. Ghelli Luserna Di Rora
14:43
2nd SOHO Italian Conference

2020 SOHO Update on R/R ALL: Is CD19-Targeted CAR-T Beneficial for O…

Feat. J. Ribera
16:49
2nd SOHO Italian Conference

2020 SOHO Updates on ALL: Does Ponatinib+Steroids Help Induce CHR in…

Feat. G. Martinelli
11:57
2nd SOHO Italian Conference

2020 SOHO Updates on Newly Diagnosed AML: Does CPX-351 Increase OS a…

Feat. C. Cerchione
10:44
2nd SOHO Italian Conference

2020 SOHO Updates on AML: Is Targeting CAMDR a New Frontier? Can E-S…

Feat. C. Cerchione
18:18
2nd SOHO Italian Conference

MD Anderson State of the Art in CLL Treatment: What Is Changing and …

Feat. A. Ferrajoli
10:10
2nd SOHO Italian Conference

2020 SOHO Updates on Newly Diagnosed AML: What Is the ORR With Aza v…

Feat. A. de la Fuente
16:49
2nd SOHO Italian Conference

2020 SOHO Update on Ph-Like ALL: How Important Are Genomic Alteratio…

Feat. M. Konopleva
19:30
2nd SOHO Italian Conference

2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy In…

Feat. T. Kadia
22:54
2nd SOHO Italian Conference

2020 SOHO Update on MPN: Ruxolitinib vs. BAT in ET, Ruxolitinib in P…

Feat. S. Verstovsek
18:07
2nd SOHO Italian Conference

2020 SOHO Update on Diagnostic Approaches to Ph-Like B-ALL: CRLF2 De…

Feat. S. Konoplev
09:51
2nd SOHO Italian Conference

2020 SOHO Update on FLT3+ AML: What Are the Novel FLT3 Inhibitors? H…

Feat. N. Daver
14:15
2nd SOHO Italian Conference

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus…

Feat. N. Daver
16:36
2nd SOHO Italian Conference

How I Manage CML at MD Anderson in 2020: How Effective & Safe Is…

Feat. E. Jabbour
13:05
2nd SOHO Italian Conference

2020 SOHO Update on Frontline Therapy Optimization in ALL: How Effec…

Feat. E. Jabbour
10:43
2nd SOHO Italian Conference

2020 SOHO Update on Frontline MDS: What Is the Role of Genomic Annot…

Feat. G. Garcia-Manero
12:20
2nd SOHO Italian Conference

2020 SOHO Update on Antibodies in AML: Is Gemtuzumab Ozogamicin Effe…

Feat. F. Ravandi
12:54
2nd SOHO Italian Conference

2020 SOHO Update on Maintenance AML: Does It Improve Clinical Outcom…

Feat. F. Ravandi